Daewoong Nabota Thriving in the US... "96% of 600,000 Customers Choose Repeat Treatments"

Cumulative Usage Exceeds 1 Million
Partner Evolus: "High Popularity Among MZ Generation"

Daewoong Pharmaceutical announced on the 13th that the number of customers enrolled in the US local loyalty program 'Evolus Rewards' for its self-developed botulinum toxin (BTX) product 'Nabota' (US product name: Jeuveau) has surpassed 600,000, with 96% of them receiving repeat treatments.

Daewoong Pharmaceutical's botulinum toxin product Nabota, marketed in the United States as 'Jeuveau'.
[Photo by Daewoong Pharmaceutical]

Evolus Rewards is a loyalty program for customers of Evolus, Daewoong Pharmaceutical's US partner, providing appointment scheduling and benefits for treatments to enrolled customers. Evolus is responsible for the distribution and marketing of Nabota in the US market.

According to Evolus, since Nabota was launched in the US market in 2020, a total of 600,000 customers have enrolled in Evolus Rewards to date. The cumulative number of treatments performed using this program has exceeded 1 million. Daewoong Pharmaceutical also stated that 96% of customers who received the first treatment registered for a second treatment, indicating high satisfaction.

Daewoong Pharmaceutical emphasized that more than half of the enrolled customers are millennials or younger generations, forecasting sustained long-term growth for Nabota. Nabota has shown an average annual sales growth rate of 62% in the US over the past two years, and its market share has surpassed 10%.

An Evolus representative said, "More than half of the Evolus Rewards registered customers are confirmed to be millennials or younger, which is a favorable indicator that can highly evaluate the potential for sustained long-term growth of the Nabota business."

Seongsoo Park, Vice President of Daewoong Pharmaceutical, stated, "Nabota is showing a high repurchase rate in the US market and satisfying young customers. It is very encouraging that within three years of entering the US market, Nabota has established itself as a leading toxin brand locally and simultaneously demonstrated continuous growth potential based on high satisfaction from patients and customers."

This content was produced with the assistance of AI translation services.